α-Synuclein Source Boundary Map

This map fixes the inclusion / delegation boundary that the active alpha-synuclein synthesis follows. It is not a synthesis page. It records which by-photo sources are considered, which already belong to a sibling topic (Parkin, Inflammation, Mitochondria, Biomarkers / Outcomes, PET / Imaging) and are linked rather than re-narrated, and which only carry a passing α-synuclein mention adequate as a Source-Table row in the topic page.

Inputs

• Canonical raw corpus: data/processed/markdown/by-photo/<stem>.md (447 sources).
• KB source notes: data/processed/kb/sources/<stem>.md carry per-page nav_path, source_headings, and quality_metrics.
• KB section page for the dominant aSyn-bearing cluster: gba-pd-asyn (198 source rows).
• Existing topic syntheses (delegations target): parkin, inflammation, mitochondria, biomarkers-outcomes, pet-imaging.
• Active topic synthesis: alpha-synuclein (Tier 1 only; this map fixes its inclusion / delegation boundary, and the topic page delegates Tier 2 / Tier 3 to sibling topics per the rules below).

Authoring Rules Carried Over

These rules apply to the topics/alpha-synuclein.md synthesis and to this map:

• Body content of data/processed/markdown/by-photo/<stem>.md is not modified; this map only reads frontmatter and headings.
• No domain-knowledge corrections; what the source records stands. (docs/decisions/2026-04-29-body-purity-and-figure-only-embeds.md, docs/decisions/2026-05-01-audit-status.md.)
• Remaining Uncertain Spans are review targets, not resolutions.
• No raw-photo staging; no new figure assets.
• Section assignment is heuristic; sources are bucketed by nav_path root, not by externally imposed taxonomy. The boundary map respects the existing section-cluster bucketing.

Keyword Set Used For Discovery

Union of literal keyword matches across by-photo bodies and source-note frontmatter (excluding the section slug gba-pd-asyn which would have matched all 198 section rows for free):

aSyn, α-syn, a-syn, α-synuclein, alpha-syn, synuclein, SNCA, SAA, seed amplification / seed-amplification, Lewy, TAK-341, MEDI1341, PFR-4067-100, WAVE, HDO, pS129, p-S129, Postmortem aSyn, Skin aSyn, PET aSyn, Animal models of aSyn, Antibodies to aSyn, aSyn programs.

The candidate set after de-duplicating is 238 distinct stems, all with confirmed data/processed/kb/sources/<stem>.md and data/processed/markdown/by-photo/<stem>.md files (no broken provenance).

Section x Tier Matrix

section	T1	T2	T3	total
gba-pd-asyn	39	69	19	127
inflammation	0	24	0	24
biomarkers-outcomes	0	15	0	15
parkin	0	14	0	14
msa	0	9	0	9
operations	0	1	7	8
samples-collaborations	0	1	7	8
pet-imaging	0	6	0	6
other-mechanisms	0	0	4	4
genetics-pathway	0	0	4	4
lysosome-autophagy	0	0	4	4
clinical-pd	0	2	2	4
lrrk2	0	0	3	3
mitochondria	0	3	0	3
molecular-biology	0	0	3	3
pk-gt-pharmacology	0	1	1	2
total	39	145	54	238

gba-pd-asyn is the dominant cluster; aSyn supplement axes account for the bulk of Tier 1. Tier 2 surfaces the cross-topic bridges (PR001 / ambroxol / venglustat in GBA-PD pilot, PARKN GT α-Syn PFF rows in Parkin, Pipeline-of-Inflammation NLRP3 cross-references, MSA pages, Brain Bank / BioOrchestra catalog). Tier 3 collects passing mentions in Operations, LRRK2, Lysosome, Genetics, Other-Mechanisms, etc., where the sibling- topic delegation is straightforward.

Tier Definitions

• Tier 1 (39 sources) — α-synuclein / aSyn / SNCA is the central axis of the page. Identified by an explicit aSyn / SNCA / Lewy / TAK-341 / MEDI1341 / WAVE / HDO / Postmortem aSyn / Skin aSyn / PET aSyn / Seed-Amplification / Spreading Models / Non-Spreading Models / Mutations SNCA / Function (of normal aSyn) / KO of α-syn / Antibodies to aSyn / Astrocytic aSyn / Oligodendrocytic aSyn / CSF & Blood (a-syn) / aSyn programs / aSyn splicing / asyn-and-mitochondria / `Pipeline of PD > aSyn
  • …/MSA > aSyn in MSA/ α-Synuclein and Lewy pathology / ATP13A2 (Park9) segment innav_path`. 79 uncertain spans, 12 body-embedded figure assets across these 39 pages, retained as review surface area.
• Tier 2 (145 sources) — α-synuclein appears as a core linking axis inside another topic that already has its own KB synthesis or its own program entity (GBA-PD / GD biology, Prevail PR001, ambroxol, venglustat, eliglustat, TAK-071, Parkin / Parkin PD with α-Syn PFF, PARKN GT, PINK-1, MSA, Brain Bank / BioOrchestra biomarker catalog, Inflammation / NLRP3 / Pyroptosis program, Mitochondria, Biomarkers-Outcomes, PET / Imaging). The α-synuclein synthesis links these rather than re-narrates them. 520 uncertain spans, 28 body-embedded figure assets.
• Tier 3 (54 sources) — single-line keyword mention; the synthesis only needs a row in the Source Table, not narrative treatment. The page belongs to (and is treated by) a non-aSyn sibling topic. 152 uncertain spans, 0 body-embedded figure assets.

Tiers are heuristic and were assigned by nav_path and source-note heading match. Borderline pages (especially Tier 1 ↔ Tier 2 in the GBA-PD Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity band, the Brain Bank / BioOrchestra Cholinergic / DLB-vs-PDD-vs-MSA catalog band, and PARKN GT α-Syn PFF rows) should be re-checked against the canonical by-photo page before quoting in synthesis.

Programs and Standalone Nav-Roots

These are the discrete therapeutic and pathology entry-points for which α-synuclein is the sole or dominant subject. The α-synuclein synthesis carries a “Programs” axis (Antibody and Immunotherapy Programs / SNCA-Knockdown Programs) that walks each of these and links to the relevant canonical page(s). All four aSyn-cluster program nav-roots (TAK-341 / MEDI1341, SNCA ASO (WAVE), SNCA BTV (HDO) (PFR-4067-100), and the aSyn programs umbrella / aSyn Propagation Suppressor) now have dedicated entity pages under entities/programs/ (tak-341, snca-aso-wave, snca-btv-hdo, asyn-propagation-suppressor); the program-level Evidence Packages, Key Source Interpretations, Source Tables, and Uncertainties Carried From Source live on those entity pages, and the topic page links them as in-axis evidence rather than re-narrating program detail. The promotion path is recorded under therapeutic-programs § Existing Entity Pages.

TAK-341 (MEDI1341) — α-synuclein-targeting monoclonal antibody (Takeda / MedImmune)

• 20240722_181822 (T1) — TAK-341 (MEDI1341) > Clinical studies — note — md

SNCA ASO — antisense oligonucleotide (WAVE Life Sciences)

• 20240722_181835 (T1) — SNCA ASO (WAVE) > Clinical plan of SNCA ASO — note — md

SNCA BTV (HDO) — heteroduplex oligonucleotide / brain-targeted vector (PFR-4067-100)

• 20240722_181831 (T1) — SNCA BTV (HDO) (PFR-4067-100) > Executive summary (Ryouta Maeda) — note — md

aSyn programs umbrella — Propagation Suppressor, Degrader

• 20240722_181827 (T1) — aSyn programs > aSyn Propagation Suppressor — note — md

α-Synuclein and Lewy pathology — supplementary disease-axis page

• 20240722_182120 (T1) — α-Synuclein and Lewy pathology in Parkinson's disease > Supplement Positive vs Negative — note — md

MSA section root — MSA > aSyn in MSA and adjacent rows

• 20240722_184156 (T1) — MSA > aSyn in MSA > CSF aSyn in MSA — note — md
• 20240722_184206 (T2) — MSA — note — md
• 20240722_184210 (T2) — MSA > Dx of MSA > Imaging — note — md
• 20240722_184216 (T2) — MSA > Outcome Measures > Unified MSA Rating Scale (UMSARS) — note — md
• 20240722_184219 (T2) — MSA > Outcome Measures > Pathology — note — md
• 20240722_184223 (T2) — MSA > Pipeline MSA > Disease-modifying — note — md
• 20240722_184226 (T2) — MSA > Pipeline MSA > Disease-modifying — note — md
• 20240722_184233 (T2) — MSA > Pathology > TM in MSA > Mucolipidosis (ML) — note — md

Pipeline of PD — aSyn antibody / vaccine / small-molecule rows

• 20240722_184327 (T1) — Pipeline of PD > aSyn - Antibody > aSyn - Small molecules — note — md
• 20240722_184330 (T1) — Pipeline of PD > aSyn - Vaccine — note — md
• 20240722_184333 (T2) — Pipeline of PD > GT — note — md
• 20240722_184351 (T2) — Pipeline of PD > 기타 MOA들 — note — md

Pipeline MSA — disease-modifying program list

• 20240722_184230 (T2) — Pipeline MSA > Subtype — note — md
• 20240722_184430 (T2) — Pipeline MSA > Disease-modifying > RBD screening question... > RBDQ-HQ (REM sleep...) > Mechanism > Pathology/Imaging — note — md

Tier 1 — α-Synuclein-Central Sources (39)

These pages are the obligatory inclusion set for topics/alpha-synuclein.md. Every row sits in sections/gba-pd-asyn (38) or in section pages whose first nav_path already names the program (PARKN GT > Quantitative BM carries the Park9 / α-Syn PFF rationale).

stem	section	nav_path	why candidate	source note	canonical	uncertain	embeds
20240722_181818	gba-pd-asyn	Pipeline of GD & GBA-PD > TAK-341 (MEDI1341) > PK/PD model	TAK-341 / MEDI1341 program (aSyn antibody)	note	md	7	4
20240722_181822	gba-pd-asyn	TAK-341 (MEDI1341) > Clinical studies	TAK-341 / MEDI1341 program (aSyn antibody)	note	md	7	2
20240722_181827	gba-pd-asyn	aSyn programs > aSyn Propagation Suppressor	aSyn programs (Propagation Suppressor / Degrader)	note	md	7	0
20240722_181831	gba-pd-asyn	SNCA BTV (HDO) (PFR-4067-100) > Executive summary (Ryouta Maeda)	SNCA BTV (HDO) / PFR-4067-100 program	note	md	10	1
20240722_181835	gba-pd-asyn	SNCA ASO (WAVE) > Clinical plan of SNCA ASO	SNCA ASO (WAVE) program	note	md	7	2
20240722_182120	gba-pd-asyn	α-Synuclein and Lewy pathology in Parkinson’s disease > Supplement Positive vs Negative	α-Synuclein and Lewy pathology entry	note	md	4	0
20240722_182149	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > a-syn POSTMORTEM	aSyn keyword present	note	md	4	0
20240722_182451	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > PET for astrocyte > aSyn > Animal models of aSyn > Non-Spreadin…	Supplement aSyn axis: ‘Animal models of aSyn’	note	md	1	0
20240722_182454	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > aSyn > Animal models of aSyn > Non-Spreading Models > Spreading…	Supplement aSyn axis: ‘Animal models of aSyn’	note	md	1	0
20240722_182457	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > aSyn > Animal models of aSyn > Spreading Models	Supplement aSyn axis: ‘Animal models of aSyn’	note	md	0	0
20240722_182501	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > aSyn > Animal models of aSyn > Non-Spreading Models > Spreading…	Supplement aSyn axis: ‘Animal models of aSyn’	note	md	0	0
20240722_182504	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Non-Spreading Models > Spreading Models > Summary of a-syn anim…	Supplement aSyn axis: ‘MOA of aSyn’	note	md	0	0
20240722_182507	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Summary of a-syn animal models > MOA of aSyn spreading > Antibo…	Supplement aSyn axis: ‘MOA of aSyn’	note	md	0	0
20240722_182510	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > MOA of aSyn spreading > Antibodies to aSyn > Astrocytic aSyn > …	Supplement aSyn axis: ‘MOA of aSyn’	note	md	1	0
20240722_182514	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Astrocytic aSyn > CSF & Blood (a-syn) > Distribution > Expressi…	Supplement aSyn axis: ‘Astrocytic aSyn’	note	md	2	0
20240722_182518	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Function (of normal aSyn) > Grading/Scoring of LB pathology > H…	Supplement aSyn axis: ‘Function (of normal aSyn’	note	md	0	0
20240722_182522	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aS… > Oligodendrocytic…	Supplement aSyn axis: ‘PET aSyn’	note	md	1	0
20240722_182524	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic …	Supplement aSyn axis: ‘PET aSyn’	note	md	0	0
20240722_182528	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic …	Supplement aSyn axis: ‘PET aSyn’	note	md	0	0
20240722_182532	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic …	Supplement aSyn axis: ‘PET aSyn’	note	md	0	0
20240722_182535	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Mutations SNCA > Neurodegeneration and aSyn > Oligodendrocytic …	Supplement aSyn axis: ‘PET aSyn’	note	md	0	0
20240722_182539	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Neurodegeneration and aSyn > Oligodendrocytic aSyn > PET aSyn >…	Supplement aSyn axis: ‘Postmortem aSyn’	note	md	1	0
20240722_182542	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Postmortem aSyn > Release > Safety for aSyn > KO of α-syn > See…	Supplement aSyn axis: ‘Postmortem aSyn’	note	md	0	0
20240722_182545	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Safety for aSyn > KO of α-syn > Seed-Amplification Assay > Quan…	Supplement aSyn axis: ‘Seed-Amplification Assay’	note	md	0	0
20240722_182549	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Seed-Amplification Assay > Quantification > Utility > Sources o…	Supplement aSyn axis: ‘Seed-Amplification Assay’	note	md	0	0
20240722_182552	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Sources of aSyn > Skin aSyn > Species > Native conformation > S…	Supplement aSyn axis: ‘Skin aSyn’	note	md	1	0
20240722_182556	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Summary aSyn species > NDE > Fragments (Truncation) > Assay Tru…	Supplement aSyn axis: ‘Summary aSyn species’	note	md	0	0
20240722_182559	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Summary aSyn species > NDE > Fragments (Truncation) > Assay Tru…	Supplement aSyn axis: ‘Summary aSyn species’	note	md	0	0
20240722_182602	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > NDE > Fragments (Truncation) > Assay Truncation > Structure of …	Supplement aSyn axis: ‘Fragments (Truncation)‘	note	md	0	0
20240722_182606	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Assay Truncation > Structure of aSyn > Synapse and aSyn > TM fo…	aSyn programs (Propagation Suppressor / Degrader)	note	md	0	0
20240722_182609	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Synapse and aSyn > TM for aSyn programs > Turnover of aSyn > AT…	aSyn programs (Propagation Suppressor / Degrader)	note	md	0	0
20240722_182613	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > ATP13A2 (Park9) > BBB / disruption / opener > BD > Process / Be…	ATP13A2 (Park9) lysosomal aSyn axis	note	md	0	0
20240722_183050	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	5	0
20240722_183135	gba-pd-asyn	Inflammation > NLRP3 > Neuronal > Caspase 1 > aSyn splicing > Catalytic cleft	Inflammation NLRP3 > aSyn splicing	note	md	3	0
20240722_183436	gba-pd-asyn	ShareFolder > Mitochondria > Astrocyte > asyn and mitochondria > Evidence in sPD	ShareFolder Mitochondria > asyn axis	note	md	4	0
20240722_184156	gba-pd-asyn	MSA > aSyn in MSA > CSF aSyn in MSA	MSA aSyn axis	note	md	4	0
20240722_184324	gba-pd-asyn	PDE > PIAS2 > Pipeline of PD > aSyn - Antibody	Pipeline of PD aSyn programs	note	md	4	0
20240722_184327	gba-pd-asyn	Pipeline of PD > aSyn - Antibody > aSyn - Small molecules	Pipeline of PD aSyn programs	note	md	4	0
20240722_184330	gba-pd-asyn	Pipeline of PD > aSyn - Vaccine	Pipeline of PD aSyn programs	note	md	1	3

Tier 2 — α-Synuclein As Linking Axis Inside Another Topic (145)

These pages have substantive α-synuclein content but their narrative center sits in a sibling topic synthesis. The α-synuclein page links them rather than re-quoting tables. Each row’s why candidate column states the bridge subject; the delegation column below states which existing topic owns the page in the current KB.

stem	section	nav_path	why candidate	source note	canonical	uncertain	embeds
20240722_181748	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary	aSyn keyword present	note	md	4	0
20240722_181752	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary	Ambroxol (CSF total / phospho-aSyn readout)	note	md	6	2
20240722_181756	gba-pd-asyn	Pipeline of GD & GBA-PD > Venglustat (Ibiglustat)	Ambroxol (CSF total / phospho-aSyn readout)	note	md	7	2
20240722_181800	gba-pd-asyn	Pipeline of GD & GBA-PD > Prevail PR001	Prevail PR001 program (insoluble aSyn / proteinase K-resistant aSyn)	note	md	8	4
20240722_181805	gba-pd-asyn	Pipeline of GD & GBA-PD > Prevail PR001	Prevail PR001 program (insoluble aSyn / proteinase K-resistant aSyn)	note	md	8	5
20240722_181809	gba-pd-asyn	Pipeline of GD & GBA-PD > Prevail PR001	Prevail PR001 program (insoluble aSyn / proteinase K-resistant aSyn)	note	md	9	4
20240722_181813	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary	aSyn keyword present	note	md	3	2
20240722_181851	parkin	AGS (Aicardi-Goutieres Syndrome) / cGAS transition > Parkin > PARK2 Gene (=PRKN)	aSyn keyword present	note	md	3	1
20240722_181855	parkin	Parkin > Parkin protein > KO Parkin	aSyn keyword present	note	md	4	0
20240722_181903	parkin	Parkin > Parkin protein > Substrates (& function) of Parkin > Parkin PD	Parkin / Parkin PD with aSyn substrate / Lewy body / α-Syn PFF rows	note	md	4	1
20240722_181943	parkin	Parkin > Parkin PD	Parkin / Parkin PD with aSyn substrate / Lewy body / α-Syn PFF rows	note	md	8	1
20240722_181947	parkin	Parkin > Parkin PD	Parkin / Parkin PD with aSyn substrate / Lewy body / α-Syn PFF rows	note	md	9	1
20240722_182001	parkin	Parkin > Parkin PD	Parkin / Parkin PD with aSyn substrate / Lewy body / α-Syn PFF rows	note	md	10	1
20240722_182007	parkin	Parkin > Parkin PD	Parkin / Parkin PD with aSyn substrate / Lewy body / α-Syn PFF rows	note	md	10	0
20240722_182011	parkin	Parkin > PARKN GT (Takeshi Hioki, PFR-4249-100)	PARKN GT (α-Syn PFF model rows / aSyn pathology decision)	note	md	4	0
20240722_182014	parkin	Parkin > PARKN GT (Takeshi Hioki, PFR-…) > Executive summary	PARKN GT (α-Syn PFF model rows / aSyn pathology decision)	note	md	3	1
20240722_182018	parkin	Parkin > PARKN GT (Takeshi Hioki, PFR-4249-100) > Clinical strategy	PARKN GT (α-Syn PFF model rows / aSyn pathology decision)	note	md	2	1
20240722_182025	parkin	Parkin > PARKN GT (Takeshi Hioki, PFR-4249-100)	PARKN GT (α-Syn PFF model rows / aSyn pathology decision)	note	md	1	0
20240722_182029	parkin	Parkin > PARKN GT (Takeshi Hioki, PFR-4249-100)	PARKN GT (α-Syn PFF model rows / aSyn pathology decision)	note	md	2	0
20240722_182050	parkin	PARKN GT (Takeshi Hioki, PFR-4249-100) > Natural Hx study > Quantitative BM criteria / Target validation	PARKN GT (α-Syn PFF model rows / aSyn pathology decision)	note	md	0	0
20240722_182116	parkin	PINK-1	PINK-1 (mentions aSyn / Lewy)	note	md	7	0
20240722_182123	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary	aSyn keyword present	note	md	5	0
20240722_182126	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity	aSyn keyword present	note	md	7	0
20240722_182130	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity	aSyn keyword present	note	md	5	0
20240722_182133	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity	aSyn keyword present	note	md	9	0
20240722_182136	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Summary GBA protein & activity, GlcCe…	aSyn keyword present	note	md	3	0
20240722_182139	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Summary GBA protein & activity	aSyn keyword present	note	md	7	0
20240722_182143	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity > Read the Paper	aSyn keyword present	note	md	7	0
20240722_182146	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity	aSyn keyword present	note	md	6	0
20240722_182153	gba-pd-asyn	Pipeline of GD & GBA-PD > Summary > GBA	aSyn keyword present	note	md	5	0
20240722_182237	gba-pd-asyn	Pipeline of GD & GBA-PD > GD > Animal models of GD	aSyn keyword present	note	md	2	0
20240722_182259	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > MOA GBA-PD	aSyn keyword present	note	md	2	0
20240722_182303	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > Motor vs Cognition	aSyn keyword present	note	md	1	0
20240722_182310	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > Correction studies	aSyn keyword present	note	md	1	0
20240722_182313	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > Correction studies	aSyn keyword present	note	md	1	0
20240722_182412	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > GalactosylSph (=psychosine) > Assay of GalactosylSph	aSyn keyword present	note	md	1	0
20240722_182617	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Process > BeyondBio > Biobank > MJF	Brain bank / postmortem aSyn-adjacent	note	md	0	0
20240722_182630	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > MJF > Netherlands Brain Bank > Imperial College Brain Bank > Ot…	Brain bank / postmortem aSyn-adjacent	note	md	0	0
20240722_182644	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Imperial College Brain Bank > Other Biobanks > Biobanks in Japa…	Brain bank / postmortem aSyn-adjacent	note	md	0	0
20240722_182708	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra	Brain bank / postmortem aSyn-adjacent	note	md	0	0
20240722_182718	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	2	0
20240722_182722	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	1	0
20240722_182725	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_182728	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	2	0
20240722_182732	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	2	0
20240722_182735	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_182738	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	2	0
20240722_182742	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_182745	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	1	0
20240722_182749	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	2	0
20240722_182808	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_182818	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	2	0
20240722_182821	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_182827	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	1	0
20240722_182830	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	1	0
20240722_182833	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	2	0
20240722_182836	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	0	0
20240722_182857	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	0	0
20240722_182900	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	1	0
20240722_182904	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	1	0
20240722_182907	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	0	0
20240722_182910	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	0	0
20240722_182919	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	0	0
20240722_182932	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	0	0
20240722_183002	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	1	0
20240722_183006	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	2	0
20240722_183009	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	1	0
20240722_183012	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_183015	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_183018	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_183021	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	4	0
20240722_183024	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	5	0
20240722_183028	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	4	0
20240722_183040	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_183047	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	2	0
20240722_183058	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_183101	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_183115	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Other Biobanks > Biobanks in Japan > BIOMARKER > BioOrchestra >…	Brain bank / postmortem aSyn-adjacent	note	md	3	0
20240722_183118	inflammation	Pyroptosis MOA	Inflammation page with aSyn cross-reference	note	md	5	0
20240722_183121	inflammation	Pipeline of Inflammation > Pyroptosis MOA > Pyroptosis evidence/MOA/Correction in PD	Inflammation page with aSyn cross-reference	note	md	3	0
20240722_183125	inflammation	Pipeline of Inflammation > Pyroptosis MOA	Inflammation page with aSyn cross-reference	note	md	5	0
20240722_183128	inflammation	Pipeline of Inflammation > Pyroptosis MOA > Pyroptosis evidence/MOA	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183138	inflammation	Cryopyrin-Associated Periodic Syndromes (CAPS)	Inflammation page with aSyn cross-reference	note	md	3	0
20240722_183141	inflammation	Pipeline of Inflammation > CAPS > WBC > Dx > ARP > Sx	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183144	inflammation	NLRP3 > Toxicity	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183147	inflammation	Inflammation > NLRP3 > Tx	Inflammation page with aSyn cross-reference	note	md	5	0
20240722_183150	inflammation	Pipeline CAPS	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183153	inflammation	Pipeline of Inflammation > Pipeline CAPS > Animal model > TM > NLRP3 inhibitor (Marianthi) (PFR-4231-100)	Inflammation page with aSyn cross-reference	note	md	5	0
20240722_183156	inflammation	NLRP3 inhibitor (Marianthi) (P…) > AD > Assays of pyroptosis	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183206	inflammation	Pipeline of Inflammation > Pipeline CAPS > NLRP3 inhibitor (Marianthi) (PFR-4231-100) > AD > Assays of…	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183208	inflammation	Assays of pyroptosis > Budget & FTE > Ceri > Chemistry	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183231	inflammation	Pipeline of Inflammation > NLRP3 inhibitor (Marianthi) > In Vivo strategy > Havrda > HED > IHC	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183234	inflammation	In Vivo strategy > Katy	Inflammation page with aSyn cross-reference	note	md	6	0
20240722_183238	inflammation	Inflammation > In Vivo strategy > Katy	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183241	inflammation	In Vivo strategy > Katy > Longitudinal	Inflammation page with aSyn cross-reference	note	md	5	0
20240722_183252	pet-imaging	PE > PET > Chemistry PET	PET imaging page with aSyn / α-Syn-related tracer / cohort	note	md	5	0
20240722_183258	pet-imaging	PET	PET imaging page with aSyn / α-Syn-related tracer / cohort	note	md	5	0
20240722_183301	pet-imaging	NHP > PDE > PE > PET	PET imaging page with aSyn / α-Syn-related tracer / cohort	note	md	1	0
20240722_183305	pk-gt-pharmacology	PK/PD > PK/PD Strategy	PK / GT pharmacology page mentioning aSyn	note	md	5	0
20240722_183314	operations	Postmortem > Proteina > Reactome > Safety	Operations / KPI / strategy page mentioning aSyn	note	md	2	0
20240722_183327	biomarkers-outcomes	Transfer > Team > Translational questions > RBD+PD	Biomarker / outcome page with aSyn readout	note	md	4	0
20240722_183332	inflammation	Stratification strategy on neuroinflammation > RNA-Seq (Daria) > C5aR1 (Woodruff, Univ of Queensland)	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183335	inflammation	Pipeline of Inflammation > Complement / C5aR1 > MOA > Woodruff’s study plan > Screening > DD	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183348	inflammation	Pipeline of Inflammation > Postmortem > Imaging of Iron > IT > Jaya	Inflammation page with aSyn cross-reference	note	md	4	0
20240722_183351	inflammation	Pyroptosis evidence/MOA…	Inflammation page with aSyn cross-reference	note	md	5	0
20240722_183354	inflammation	Minee Choi > Kv1.3 > Kyoko Yoshikawa > Lee Jonghun	Inflammation page with aSyn cross-reference	note	md	2	0
20240722_183426	mitochondria	Magnetoencephalography (MEG) > Maiko Tanaka > Metabolomics > MIBG	Mitochondria page mentioning aSyn	note	md	5	0
20240722_183518	gba-pd-asyn	Studies of 31P MRS > Oliver Bandmann, MD,… > MELAS (Mitochondrial enc…) > MJFF	aSyn keyword present	note	md	4	0
20240722_183521	inflammation	Stratification strategy on…	Inflammation page with aSyn cross-reference	note	md	5	0
20240722_184149	mitochondria	mitophagy in vivo… > Monthly update > MRI > Classification	Mitochondria page mentioning aSyn	note	md	4	0
20240722_184200	gba-pd-asyn	Brain Bank	Brain bank / postmortem aSyn-adjacent	note	md	6	0
20240722_184203	gba-pd-asyn	Brain Bank > Clinical Progression > Clinical Trial example > Cohort	Brain bank / postmortem aSyn-adjacent	note	md	4	0
20240722_184206	msa	MSA	MSA section page (aSyn cross-reference)	note	md	1	0
20240722_184210	msa	MSA > Dx of MSA > Imaging	MSA section page (aSyn cross-reference)	note	md	3	0
20240722_184213	biomarkers-outcomes	NFL	Biomarker / outcome page with aSyn readout	note	md	6	0
20240722_184216	msa	MSA > Outcome Measures > Unified MSA Rating Scale (UMSARS)	MSA section page (aSyn cross-reference)	note	md	5	0
20240722_184219	msa	MSA > Outcome Measures > Pathology	MSA section page (aSyn cross-reference)	note	md	2	0
20240722_184223	msa	MSA > Pipeline MSA > Disease-modifying	MSA section page (aSyn cross-reference)	note	md	2	0
20240722_184226	msa	MSA > Pipeline MSA > Disease-modifying	MSA section page (aSyn cross-reference)	note	md	4	0
20240722_184230	msa	Pipeline MSA > Subtype	Pipeline MSA program / cohort	note	md	5	0
20240722_184233	msa	MSA > Pathology > TM in MSA > Mucolipidosis (ML)	MSA section page (aSyn cross-reference)	note	md	4	0
20240722_184253	biomarkers-outcomes	NFL > PD	Biomarker / outcome page with aSyn readout	note	md	4	0
20240722_184300	biomarkers-outcomes	Outcome measures > Original UPDRS (1987)	Biomarker / outcome page with aSyn readout	note	md	5	0
20240722_184310	inflammation	Stratification strategy on… > Pathogenicity of variant	Inflammation page with aSyn cross-reference	note	md	3	0
20240722_184333	clinical-pd	Pipeline of PD > GT	Clinical PD page mentioning aSyn	note	md	7	2
20240722_184351	clinical-pd	Pipeline of PD > 기타 MOA들	Clinical PD page mentioning aSyn	note	md	5	0
20240722_184401	samples-collaborations	Pittsburgh University > Burton Lab	Samples / Brain bank / collaboration page mentioning aSyn	note	md	2	0
20240722_184413	gba-pd-asyn	PD and PGRN > MJF > Prophylactic vs Therapeutic > Protein tags	aSyn keyword present	note	md	3	0
20240722_184430	msa	Pipeline MSA > Disease-modifying > RBD screening question… > RBDQ-HQ (REM sleep…) > Mechanism > Pa…	Pipeline MSA program / cohort	note	md	3	0
20240722_184434	biomarkers-outcomes	RBD	Biomarker / outcome page with aSyn readout	note	md	4	0
20240722_184437	gba-pd-asyn	RBD PDD/DLB > GBA pathway in RBD > NCNP collaboration for RBD > Reference range (normal range)	aSyn keyword present	note	md	4	0
20240722_184440	biomarkers-outcomes	Retina > Issues Retina > Rob Rubens	Biomarker / outcome page with aSyn readout	note	md	4	0
20240722_184450	biomarkers-outcomes	Outcome measures > Sandy > Screenig > Scientst.com > Schizophrenia	Biomarker / outcome page with aSyn readout	note	md	4	0
20240722_184456	biomarkers-outcomes	MoCA (Montreal Cognitive…	Biomarker / outcome page with aSyn readout	note	md	4	0
20240722_184503	biomarkers-outcomes	SCOPA-AUT > Shipment > Sigma-1 Receptor (σ1R) > σ1R PET > SILK	Biomarker / outcome page with aSyn readout	note	md	5	0
20240722_184506	biomarkers-outcomes	biomarkers	Biomarker / outcome page with aSyn readout	note	md	2	0
20240722_184513	biomarkers-outcomes	Succinate > Surrogate endpoint > Symptom > Synapse	Biomarker / outcome page with aSyn readout	note	md	3	0
20240722_184519	biomarkers-outcomes	Synapse > Neuronal pentraxins > Synaptic change in PD > Target Identification > TDP43 > TMEM106B > TME…	Biomarker / outcome page with aSyn readout	note	md	5	0
20240722_184535	mitochondria	TRAP1 > MOA	Mitochondria page mentioning aSyn	note	md	4	0
20240722_184545	biomarkers-outcomes	RBDQ-HO (REM sleep…	Biomarker / outcome page with aSyn readout	note	md	3	0
20240722_184557	biomarkers-outcomes	Reference range (normal range)	Biomarker / outcome page with aSyn readout	note	md	3	0
20240722_184600	biomarkers-outcomes	Rob Rubens	Biomarker / outcome page with aSyn readout	note	md	4	0
20240722_184809	pet-imaging	[MOLECULAR BIOLOGY] > [PET] > Parameters of PET ligand	PET imaging page with aSyn / α-Syn-related tracer / cohort	note	md	6	0
20240722_184823	pet-imaging	[MOLECULAR BIOLOGY] > [PET] > Parameters of PET ligand	PET imaging page with aSyn / α-Syn-related tracer / cohort	note	md	5	0
20240722_184826	pet-imaging	Dose of PET tracer > PET Steering Committee > Workflow > Preclinical study	PET imaging page with aSyn / α-Syn-related tracer / cohort	note	md	5	0

Tier 3 — Passing Mention; Source-Table Row Only (54)

Single-line aSyn / α-syn / SNCA / Lewy mentions inside larger pages that are clearly about a different topic. The synthesis records each of these only in the Source Table; no narrative section. They stay under their existing section page.

stem	section	nav_path	why candidate	source note	canonical	uncertain	embeds
20240722_181741	gba-pd-asyn	Pipeline of GD & GBA-PD	aSyn keyword present	note	md	3	0
20240722_182230	gba-pd-asyn	Pipeline of GD & GBA-PD > GD > Parameters > GD 3 Summary	aSyn keyword present	note	md	4	0
20240722_182233	gba-pd-asyn	Pipeline of GD & GBA-PD > GD > Animal models of GD	Eliglustat / GBA-PD pilot biomarker context	note	md	1	0
20240722_182241	gba-pd-asyn	Pipeline of GD & GBA-PD > GD > Animal models of GD > Outcome measure in nGD	aSyn keyword present	note	md	2	0
20240722_182306	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > Animal models of GBA-PD	aSyn keyword present	note	md	0	0
20240722_182333	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > PET Imaging GBA > GBA Activator	aSyn keyword present	note	md	2	0
20240722_182339	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA GT > Executive summary	aSyn keyword present	note	md	2	0
20240722_182343	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA GT > NHP studies > SNBR (Shin Nippon Biomedical Laboratories)	aSyn keyword present	note	md	0	0
20240722_182346	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA GT > TM GT GBA-PD	aSyn keyword present	note	md	0	0
20240722_182351	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > NHP Translational Model	aSyn keyword present	note	md	1	0
20240722_182355	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Competitor	aSyn keyword present	note	md	1	0
20240722_182358	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Competitor > Fusion Protein	aSyn keyword present	note	md	0	0
20240722_182402	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > RD DDU’s PET Imaging GBA	aSyn keyword present	note	md	0	0
20240722_182406	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Acid ceramidase inhibitor	aSyn keyword present	note	md	1	0
20240722_182409	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > GALC (galactosylceramidase) > Genetics GALC for PD	aSyn keyword present	note	md	2	0
20240722_182416	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Pipeline of KD > Target validation and correction	aSyn keyword present	note	md	1	0
20240722_182419	gba-pd-asyn	Pipeline of GD & GBA-PD > GBA-PD > GBA Activator > Target validation and correction > 총정리중 GBA+PD에서 Lys	aSyn keyword present	note	md	0	0
20240722_182440	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Gut > Commissures > Anatomy-Neurological signs > General	aSyn keyword present	note	md	2	0
20240722_182447	gba-pd-asyn	Pipeline of GD & GBA-PD > Supplement > Antibody > Epitope mapping > APOE > AQP4 potentiator	aSyn keyword present	note	md	0	0
20240722_183311	operations	Reactome > Safety	Operations / KPI / strategy page mentioning aSyn	note	md	4	0
20240722_183324	other-mechanisms	TAU > TCP > Timeline	Other-mechanism page mentioning aSyn	note	md	4	0
20240722_183339	operations	DD > Progress	Operations / KPI / strategy page mentioning aSyn	note	md	4	0
20240722_183358	samples-collaborations	Liquid Nitrogen > Longitudinal	Samples / Brain bank / collaboration page mentioning aSyn	note	md	5	0
20240722_183401	lrrk2	Longitudinal > 4 LRRK2 > Animal models of LRRK2 > Inflammation and LRRK2	LRRK2 page mentioning aSyn	note	md	3	0
20240722_183404	genetics-pathway	Mutation	Genetics / pathway page mentioning aSyn	note	md	4	0
20240722_183407	lrrk2	Pipeline of LRRK2 > Summary (Schneider…) > DNL201 (=GNE-7…) > Clinical trials	LRRK2 page mentioning aSyn	note	md	3	0
20240722_183410	lrrk2	DNL151 (=BIIB12…) > Clinical trials > Preclinical	LRRK2 page mentioning aSyn	note	md	3	0
20240722_183416	lysosome-autophagy	Lysosomal Enzymes	Lysosome page mentioning aSyn	note	md	5	0
20240722_183419	lysosome-autophagy	RD-DDU > Lysosomal changes in PD > Lysosomal Enzymes > Assessment of lysosome > Marker	Lysosome page mentioning aSyn	note	md	4	0
20240722_183423	lysosome-autophagy	Macroautophagy > Microautophagy > CMA > BMP (Bis(monoacylglycero…))	Lysosome page mentioning aSyn	note	md	4	0
20240722_183429	operations	Milestones (process)	Operations / KPI / strategy page mentioning aSyn	note	md	6	0
20240722_184237	samples-collaborations	NDU > DDU Subteam > 20201022 Kick off > Sharefolder	Samples / Brain bank / collaboration page mentioning aSyn	note	md	3	0
20240722_184240	operations	Sharefolder > Neurodegeneration	Operations / KPI / strategy page mentioning aSyn	note	md	5	0
20240722_184244	samples-collaborations	Neurogenomics Partnership	Samples / Brain bank / collaboration page mentioning aSyn	note	md	4	0
20240722_184317	genetics-pathway	PADD > Pathogenicity of variant > Pathway Analysis > Example of Pathway Analysis	Genetics / pathway page mentioning aSyn	note	md	6	0
20240722_184340	other-mechanisms	기타 MOA들	Other-mechanism page mentioning aSyn	note	md	2	0
20240722_184354	other-mechanisms	기타 MOA들	Other-mechanism page mentioning aSyn	note	md	3	0
20240722_184404	clinical-pd	Prodromal PD > Definition of Prodromal PD > MDS research criteria for prodromal PD	Clinical PD page mentioning aSyn	note	md	4	0
20240722_184407	clinical-pd	Takeda efforts in prodromal PD	Clinical PD page mentioning aSyn	note	md	3	0
20240722_184410	samples-collaborations	P2P Platform Trial > Progranulin (PGRN) > Denali Progranulin PTV > PD and PGRN	Samples / Brain bank / collaboration page mentioning aSyn	note	md	5	0
20240722_184417	molecular-biology	PD Proteomics	Molecular biology / proteomics page mentioning aSyn	note	md	4	0
20240722_184459	operations	Sharefolder	Operations / KPI / strategy page mentioning aSyn	note	md	2	0
20240722_184509	genetics-pathway	Example of Pathway Analy…	Genetics / pathway page mentioning aSyn	note	md	5	0
20240722_184522	samples-collaborations	P2P > TMQB > Toxins > Paraquat > MPTP	Samples / Brain bank / collaboration page mentioning aSyn	note	md	4	0
20240722_184525	samples-collaborations	P2P	Samples / Brain bank / collaboration page mentioning aSyn	note	md	3	0
20240722_184529	samples-collaborations	P2P Platform Trial	Samples / Brain bank / collaboration page mentioning aSyn	note	md	4	0
20240722_184532	molecular-biology	Proteomics > Issues and Solving	Molecular biology / proteomics page mentioning aSyn	note	md	0	0
20240722_184542	lysosome-autophagy	TRPML1	Lysosome page mentioning aSyn	note	md	4	0
20240722_184629	genetics-pathway	(empty)	Genetics / pathway page mentioning aSyn	note	md	4	0
20240722_184656	molecular-biology	Protein-Protein Interaction (PPI) > Post-Translational Modifications	Molecular biology / proteomics page mentioning aSyn	note	md	4	0
20240722_184700	other-mechanisms	UPS > Metabolomics > Omics > Cis- vs Trans- > Intracellular delivery	Other-mechanism page mentioning aSyn	note	md	1	0
20240722_184749	pk-gt-pharmacology	Life-cycle > Localization > Manufacturing > PK/PD strategy	PK / GT pharmacology page mentioning aSyn	note	md	4	0
20240722_184847	operations	FY21 > FY21 MRP	Operations / KPI / strategy page mentioning aSyn	note	md	4	0
20240722_184850	operations	[Budget] > FY21 > FY21 B. KPI-linked proje…	Operations / KPI / strategy page mentioning aSyn	note	md	3	0

Exclusion / Delegation Rules

The topics/alpha-synuclein.md synthesis follows these rules:

• Parkin-central pages stay in parkin; the α-synuclein page links to them when discussing Parkin↔aSyn cross-talk (α-Syn PFF model rows in PARKN GT, synphilin-1 / aSyn (?) substrate-list mentions, Lewy-body autopsy notes). Do not re-narrate Parkin protein / Parkin PD / PARKN GT executive summary here. Sources delegated: 20240722_181851, _181855, _181903, _181943, _181947, _182001, _182007, _182011, _182014, _182018, _182025, _182029, _182050, _182116.
• Inflammation-central pages stay in inflammation; aSyn-splicing / Pyroptosis / NLRP3 / CAPS / C5aR1 / Stratification cross-references link to the inflammation page. Sources delegated: 20240722_183118 through 20240722_183354 cluster (24 stems incl. Pyroptosis MOA, CAPS, NLRP3 inhibitor (Marianthi), In Vivo strategy / Katy / Havrda, Complement / C5aR1, RNA-Seq).
• Mitochondria-central pages stay in mitochondria; the α-synuclein page links the asyn and mitochondria evidence and the TRAP1 / mitophagy axis. Sources delegated: 20240722_183426, 20240722_183518, 20240722_184149, 20240722_184535. The lone Tier 1 mitochondria-bridge 20240722_183436 (ShareFolder > Mitochondria > Astrocyte > asyn and mitochondria) is retained on the α-synuclein side because its first nav_path segment is ShareFolder and the page’s central content is the asyn and mitochondria evidence-in-sPD bundle.
• Biomarkers-and-outcomes pages stay in biomarkers-outcomes; the α-synuclein page references CSF aSyn / RBD / SAA biomarker development, σ1R, NFL, retinal aSyn / Amydis, Synaptic biomarkers, Reference range (normal range), Outcome measures rows. Sources delegated: 15 stems in sections/biomarkers-outcomes (NFL, RBD, Retina, MoCA, SCOPA-AUT, biomarkers, Synapse, Surrogate endpoint, Reference range, Rob Rubens).
• PET-imaging-central pages stay in pet-imaging; aSyn PET / immunoPET / propagation-imaging cross-references link there. Sources delegated: 6 stems in sections/pet-imaging (20240722_183252, _183258, _183301, _184809, _184823, _184826).
• GBA-PD pilot synthesis pages (gba-pd, gba-therapeutics, biomarkers (GBA-PD pilot)) and the per-compound entity pages (eliglustat, ambroxol, venglustat, PR001) carry the GBA-PD pilot α-synuclein readouts. The α-synuclein synthesis links them under a “GBA-PD ↔ aSyn” axis instead of re-narrating Insoluble α-synuclein in 4L/PS-NA, Proteinase K-resistant aSyn, phospho-α-synuclein CSF cells. Sources delegated: 20240722_181748, _181752, _181756, _181800, _181805, _181809, _181813.
• Brain Bank / BioOrchestra biomarker-catalog cluster (20240722_182617 → 20240722_183115): treat as an external evidence catalog. The α-synuclein synthesis would link the Postmortem / Braak Staging / DLB-vs-PDD-vs-MSA / Cholinergic / NBB / Mesenex aSyn immunotx rows by stem reference, not table re-quote. Cluster ownership now active: brain-banks-postmortem (Cluster D, _182617–_182704, _184200, _184203) and bioorchestra-biomarker-catalog (Cluster C, _182708–_183115 minus Tier 1 _183050).
• MSA cluster (sections/msa, 9 stems). Resolution: the α-synuclein synthesis owns the Tier 1 aSyn in MSA > CSF aSyn in MSA axis (20240722_184156), and the new whole-section synthesis msa is the primary owner of the 9 MSA Tier 2 sources for diagnosis (Gilman 2008 three-level criteria), UMSARS / MSA-QoL / ICLEMSA outcome measures, NfL CSF / blood biomarker, pathology (Inclusions, cell loss, splice, subtype comparison), Pipeline MSA disease-modifying / symptomatic inventory, RBD-as-MSA-prodrome screening, and the Mucolipidosis (ML) TM in MSA cross-reference. The α-synuclein page links to topics/msa for that material rather than carrying it.

Synthesis Shape

The active topics/alpha-synuclein.md synthesis adopts this axis menu (each axis with one or two paragraphs, anchored on canonical-by-photo links by stem):

1. Foundational biology — structure, function, native conformation, homology, expression, distribution, fragments / truncation, synapse, turnover, KO of α-syn, safety. Sources: 20240722_182514, _182518, _182549, _182552, _182556, _182559, _182602, _182606, _182609, _182542, _182545.
2. Mutations and SNCA genetics — Mutations SNCA, Neurodegeneration and aSyn, oligodendrocytic aSyn, astrocytic aSyn. Sources: 20240722_182522, _182524, _182528, _182532, _182535, _182514, _182510.
3. Animal models — Spreading and Non-Spreading — PFF, A53T, BAC, PrP-A53T-SNCA, summary tables. Sources: 20240722_182451, _182454, _182457, _182501, _182504, _182507.
4. Postmortem / brain-bank pathology — Braak Staging, Lewy-body scoring, DLB / PDD / MSA differential, NBB / Imperial / Netherlands / MJF / Biobanks-in-Japan. Sources: 20240722_182539, _182539, _182149, _182518, _182722, _182904, _182907, _182910, _184200, _184203, plus delegated rows under gba-pd-asyn Brain Bank cluster.
5. Seed-Amplification Assay (SAA) / quantification / utility — Sources: 20240722_182542, _182545, _182549. SAA is also the anchor for the RBD / prodromal stratification thread (link to biomarkers-outcomes RBD axis).
6. Antibody and immunotherapy programs — TAK-341 / MEDI1341 (20240722_181818, _181822), Pipeline-of-PD aSyn-Antibody / aSyn-Vaccine / aSyn-Small-molecules (20240722_184324, _184327, _184330), Antibodies-to-aSyn supplement (20240722_182507, _182510), aSyn (therapeutic) antibody from inflammation cluster (20240722_183050).
7. SNCA-knockdown programs — SNCA ASO (WAVE) (20240722_181835), SNCA BTV (HDO) / PFR-4067-100 (20240722_181831), aSyn programs umbrella with Propagation Suppressor / Degrader (20240722_181827, _182606, _182609).
8. GBA-PD ↔ aSyn link — link out to GBA-PD pilot (gba-pd, gba-therapeutics, PR001, ambroxol, venglustat); record the biomarker readouts (insoluble aSyn in 4L/PS-NA, proteinase K-resistant aSyn, CSF total / phospho-aSyn) without re-quoting tables. Source bridges: 20240722_181748 through _181813, _182149, _182303, _182310, _182313, _182419, _182437.
9. Parkin / mitophagy ↔ aSyn link — link out to parkin and PARKN GT; record α-Syn PFF rows and synphilin-1 / aSyn (?) substrate notes by stem reference.
10. Inflammation ↔ aSyn link — link out to inflammation for aSyn splicing, pyroptosis, neuroinflammation strands.
11. Mitochondria ↔ aSyn link — link out to mitochondria for asyn-and- mitochondria, TRAP1, mitophagy cross-references.
12. PET / imaging ↔ aSyn link — link out to pet-imaging for PET aSyn / immunoPET / propagation-imaging axes.
13. MSA aSyn axis — own the MSA > aSyn in MSA > CSF aSyn in MSA axis (no MSA topic synthesis exists). Source: 20240722_184156, plus delegated sections/msa rows for cohort / disease-modifying program inventory.
14. Lewy pathology entry — α-Synuclein and Lewy pathology in Parkinson's disease > Supplement Positive vs Negative (20240722_182120).

This ordering keeps sibling-topic delegations narrow and avoids re-narrating Parkin / Inflammation / Mitochondria / Biomarkers-Outcomes / PET-Imaging content already synthesised.

Risk and Uncertainty Notes

High-uncertainty pages worth re-checking before quoting

These are the 15 stems with the highest uncertain_span_count among the 238 candidates. They sit primarily in the GBA-PD Pilot and the Brain Bank / BioOrchestra catalog; cell-level numerics should be re-verified against the canonical page rather than re-quoted from a secondary table.

• 20240722_181831 (T1, gba-pd-asyn) — uncertain_span_count=10, embedded_image_count=1 — SNCA BTV (HDO) (PFR-4067-100) > Executive summary (Ryouta Maeda) — note
• 20240722_182001 (T2, parkin) — uncertain_span_count=10, embedded_image_count=1 — Parkin > Parkin PD — note
• 20240722_182007 (T2, parkin) — uncertain_span_count=10, embedded_image_count=0 — Parkin > Parkin PD — note
• 20240722_181809 (T2, gba-pd-asyn) — uncertain_span_count=9, embedded_image_count=4 — Pipeline of GD & GBA-PD > Prevail PR001 — note
• 20240722_181947 (T2, parkin) — uncertain_span_count=9, embedded_image_count=1 — Parkin > Parkin PD — note
• 20240722_182133 (T2, gba-pd-asyn) — uncertain_span_count=9, embedded_image_count=0 — Pipeline of GD & GBA-PD > Summary > 총정리 GBA protein & activity — note
• 20240722_181800 (T2, gba-pd-asyn) — uncertain_span_count=8, embedded_image_count=4 — Pipeline of GD & GBA-PD > Prevail PR001 — note
• 20240722_181805 (T2, gba-pd-asyn) — uncertain_span_count=8, embedded_image_count=5 — Pipeline of GD & GBA-PD > Prevail PR001 — note
• 20240722_181943 (T2, parkin) — uncertain_span_count=8, embedded_image_count=1 — Parkin > Parkin PD — note
• 20240722_181756 (T2, gba-pd-asyn) — uncertain_span_count=7, embedded_image_count=2 — Pipeline of GD & GBA-PD > Venglustat (Ibiglustat) — note
• 20240722_181818 (T1, gba-pd-asyn) — uncertain_span_count=7, embedded_image_count=4 — Pipeline of GD & GBA-PD > TAK-341 (MEDI1341) > PK/PD model — note
• 20240722_181822 (T1, gba-pd-asyn) — uncertain_span_count=7, embedded_image_count=2 — TAK-341 (MEDI1341) > Clinical studies — note
• 20240722_181827 (T1, gba-pd-asyn) — uncertain_span_count=7, embedded_image_count=0 — aSyn programs > aSyn Propagation Suppressor — note
• 20240722_181835 (T1, gba-pd-asyn) — uncertain_span_count=7, embedded_image_count=2 — SNCA ASO (WAVE) > Clinical plan of SNCA ASO — note
• 20240722_182116 (T2, parkin) — uncertain_span_count=7, embedded_image_count=0 — PINK-1 — note

Pages with body-embedded figures (TIER review priority)

Pages with embedded_image_count > 0 carry figure assets in body under data/processed/assets/by-photo/<stem>/. The synthesis does not re-embed these; it links the canonical page and lets the reader open it. (Body-purity rule: docs/decisions/2026-04-29-body-purity-and-figure-only-embeds.md.)

• 20240722_181805 (T2, gba-pd-asyn) — embedded_image_count=5 — Pipeline of GD & GBA-PD > Prevail PR001
• 20240722_181800 (T2, gba-pd-asyn) — embedded_image_count=4 — Pipeline of GD & GBA-PD > Prevail PR001
• 20240722_181809 (T2, gba-pd-asyn) — embedded_image_count=4 — Pipeline of GD & GBA-PD > Prevail PR001
• 20240722_181818 (T1, gba-pd-asyn) — embedded_image_count=4 — Pipeline of GD & GBA-PD > TAK-341 (MEDI1341) > PK/PD model
• 20240722_184330 (T1, gba-pd-asyn) — embedded_image_count=3 — Pipeline of PD > aSyn - Vaccine
• 20240722_181752 (T2, gba-pd-asyn) — embedded_image_count=2 — Pipeline of GD & GBA-PD > Summary
• 20240722_181756 (T2, gba-pd-asyn) — embedded_image_count=2 — Pipeline of GD & GBA-PD > Venglustat (Ibiglustat)
• 20240722_181813 (T2, gba-pd-asyn) — embedded_image_count=2 — Pipeline of GD & GBA-PD > Summary
• 20240722_181822 (T1, gba-pd-asyn) — embedded_image_count=2 — TAK-341 (MEDI1341) > Clinical studies
• 20240722_181835 (T1, gba-pd-asyn) — embedded_image_count=2 — SNCA ASO (WAVE) > Clinical plan of SNCA ASO
• 20240722_184333 (T2, clinical-pd) — embedded_image_count=2 — Pipeline of PD > GT
• 20240722_181831 (T1, gba-pd-asyn) — embedded_image_count=1 — SNCA BTV (HDO) (PFR-4067-100) > Executive summary (Ryouta Maeda)
• 20240722_181851 (T2, parkin) — embedded_image_count=1 — AGS (Aicardi-Goutieres Syndrome) / cGAS transition > Parkin > PARK2 Gene (=PRKN)
• 20240722_181903 (T2, parkin) — embedded_image_count=1 — Parkin > Parkin protein > Substrates (& function) of Parkin > Parkin PD
• 20240722_181943 (T2, parkin) — embedded_image_count=1 — Parkin > Parkin PD
• 20240722_181947 (T2, parkin) — embedded_image_count=1 — Parkin > Parkin PD
• 20240722_182001 (T2, parkin) — embedded_image_count=1 — Parkin > Parkin PD
• 20240722_182014 (T2, parkin) — embedded_image_count=1 — Parkin > PARKN GT (Takeshi Hioki, PFR-...) > Executive summary
• 20240722_182018 (T2, parkin) — embedded_image_count=1 — Parkin > PARKN GT (Takeshi Hioki, PFR-4249-100) > Clinical strategy

Boundary ambiguity hot spots

• GBA-PD Summary > 총정리 GBA protein & activity band (10 pages, 20240722_182123 → 20240722_182153): aSyn rows appear as part of GBA biomarker matrices. Tier 2 here; the GBA-PD pilot synthesis owns this band. Risk of double-narration if the α-synuclein page treats these as Tier 1. Cross-check against gba-pd when writing.
• PARKN GT α-Syn PFF rows (20240722_182025, _182050): α-Syn PFF is one of three preclinical models (alongside MPTP and 6-OHDA); α-synuclein page should link, not re-quote. Risk: the PARKN GT decision matrix uses α-syn pathology absence as a patient-selection criterion (see Parkin synthesis line ≈265–275: “aSyn-related biomarkers are not planned for this project because aSyn pathology is rarely observed in the target population”), which is a meaningful scope contradiction worth surfacing in the α-synuclein synthesis.
• Brain Bank / BioOrchestra Cholinergic / DLB-vs-PDD-vs-MSA cluster (20240722_182617 → 20240722_183115): biomarker catalog rows that list α-syn / Mesenex αSyn immunotx / synuclein-only inclusions / α-syn fibrils diagram alongside many non-aSyn rows. These were classified Tier 2 (catalog reference) rather than Tier 1, but individual pages with strong propagation / Braak / Masuda-Suzukake α-syn fibrils content (e.g. 20240722_182722) should be promoted to Tier 1 by the synthesis writer if the body confirms central focus. Cluster C / D ownership now active: bioorchestra-biomarker-catalog and brain-banks-postmortem.
• Inflammation In Vivo strategy > Katy cluster (20240722_183234, _183238, _183241): Katy’s longitudinal in-vivo neuroinflammation protocol uses α-synuclein PFF as the seeding model. Tier 2 because the page owner is topics/inflammation; the α-synuclein synthesis should still cite the PFF link.
• Pipeline of PD GT page (20240722_184333): classified Tier 2. The page lists program candidates (aSyn-Antibody / Vaccine / Small molecules / GT) without α-syn-specific narrative. The adjacent _184327 and _184330 are Tier 1 because they own the aSyn-Antibody / Vaccine subtree.
• α-Synuclein and Lewy pathology in Parkinson's disease > Supplement Positive vs Negative (20240722_182120): single Tier 1 page on this exact nav-root. The supplement is small but is the canonical Lewy-pathology entry; treat as the anchor for the “Lewy pathology” axis.

Cluster size risk

• The aSyn supplement chain is structurally a long single-thread of inherited nav_path (each page picks up where the previous left off), not an independently bucketed sub-tree. Reading order matters; the synthesis writer should walk pages in capture-time order for the Pipeline of GD & GBA-PD > Supplement > … aSyn … band and the MOA / Animal-Models band rather than alphabetising by axis.
• The 14 PARKN-GT-and-Parkin Tier 2 rows already have a synthesis (parkin). Re-checking that synthesis is cheaper than re-narrating from raw photo notes.
• 0 Pipeline of Inflammation > NLRP3 Tier 1 pages exist beyond 20240722_183135 (aSyn splicing segment in nav-path). The inflammation page already covers cross-talk, so the α-synuclein synthesis can lean on its single-row link instead.

Cross-References

• KB Index
• Build Note
• α-Synuclein
• GBA-PD, GD, α-Synuclein Pipeline
• MSA
• Parkin
• Inflammation
• Biomarkers and Outcomes
• PET, Imaging, and Tracer Development
• Mitochondria
• Parkin
• Inflammation
• Mitochondria
• Biomarkers and Outcomes
• PET, Imaging, and Tracer Development
• PR001
• Ambroxol
• Venglustat
• PARKN GT
• Navigation Path Index
• Source Catalog